Patheon will showcase its offerings, including non-sterile, sterile and softgel dose forms at CPhI/ICSE in Messe Frankfurt, Germany, 22-24 October.

Patheon’s Harry Gill, senior vice-president, quality and continuous improvement, will present ‘Utilizing Operational Excellence Principles to Drive Quality Improvements’ on Wednesday 23 October at 2.30pm, CET in Hall 4.2 Booth L52.

During the presentation, Gill will discuss how the company’s Patheon Advantage II programme has been one of the main drivers of its efficiency improvement efforts. Patheon has utilized these same philosophies to create improvements in its quality performance, in particular Right First Time, which is a key performance indicator for both Patheon and its clients.

In addition, many Patheon executives, technical and scientific experts will also attend CPhI/ICSE and will be available to discuss Patheon’s non-sterile, sterile and softgel capabilities for development and commercial. Patheon’s experience encompasses thousands of projects for pharmaceutical and biotechnology companies of all types and sizes.

The company gives access to the expertise, proven quality and global resources to bring drug candidates from preclinical stages through commercial production. Patheon will be exhibiting at Hall 4.2, Booth 42G03 for the duration of the conference.

CPhI Worldwide 2013 is the world’s leading pharmaceutical networking event and is co-located with ICSE, P-MEC Europe & InnoPack. The unique event attracts more than 29,500 attendees from over 130 countries and 2,200 exhibitors.